S-1/A: Curanex Pharmaceuticals Launches IPO to Fund Botanical Drug Development for Inflammatory Diseases

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs, is launching an initial public offering of 3.75 million shares to raise approximately $12.1 million, aiming to advance its lead candidate Phyto-N into clinical trials for ulcerative colitis and other inflammatory conditions.

Summary

• Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company focused on discovering, developing, and commercializing innovative botanical drugs for inflammatory diseases.
• The company's lead drug candidate, Phyto-N, is a proprietary botanical extract with a long history of use in Chinese traditional medicine, showing positive results in animal models for ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout.
• Curanex is conducting an Initial Public Offering (IPO) of 3,750,000 shares of common stock on a firm commitment underwritten basis, with an expected price range of US$4.00 to US$6.00 per share.
• The company expects to receive approximately $12,114,369 in net proceeds from the IPO (at the lower end of the price range), which will be used primarily for research and development, including FDA-required studies and clinical trials.
• An additional 1,750,000 shares are being registered for resale by existing selling stockholders, from which the company will not receive any proceeds.
• Curanex has applied to list its Common Stock on The Nasdaq Capital Market under the symbol CURX, which is a condition to the closing of the offering.
• The company reported a net loss of $(137,583) for the three months ended March 31, 2025, and $(361,506) for the fiscal year ended December 31, 2024, with no revenue generated in these periods.
• As of March 31, 2025, cash and cash equivalents totaled $198,943, with an accumulated deficit of $(760,032).
• The company estimates it will require over $150 million to execute its full business plan through FDA approval and product launch, with the initial phase (IND submission and Phase I/II for ulcerative colitis) estimated at $12 million over 18-24 months.
• Founders and their immediate family beneficially own approximately 80.0% of outstanding common stock pre-IPO and will own approximately 69.3% of voting stock post-IPO, making Curanex a controlled company under Nasdaq standards.
• The company underwent a reincorporation from New York to Nevada on June 10, 2024, and acquired intellectual property assets (provisional patent applications and animal study reports) from a related party, Duraviva Pharma Inc., on June 17, 2024.
• A 3-for-5 reverse stock split became effective on November 19, 2024, resulting in 24,000,000 post-split shares outstanding.
• The company has received two loans totaling $400,000 from Dian Ying Jing, a founder and the Secretary, in February and May 2025, to support IPO-related costs and working capital.

Sentiment

Score: 4

Explanation: The company is in a very early developmental stage with no revenue and significant accumulated losses, indicating high financial risk. While preclinical data for its lead candidate Phyto-N is promising and the IPO aims to secure initial funding, the path to commercialization for botanical drugs is long, expensive, and highly uncertain, with substantial future capital needs. The controlled company structure also presents potential governance considerations for public shareholders.

Positives

• Phyto-N, the lead drug candidate, has shown positive results in preclinical animal models across six inflammatory diseases, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout.
• Phyto-N has a long history of human use in Chinese traditional medicine (over 30 years), providing encouraging insights into its potential therapeutic effects and tolerability.
• The company's proprietary platform for identifying, extracting, and optimizing anti-inflammatory compounds from medicinal plants is a competitive strength.
• Management believes the company's current cash position, recent shareholder loans, and anticipated IPO proceeds are sufficient to fund operations for at least the next twelve months, alleviating substantial doubt about going concern.
• The company has a clear roadmap to submit an Investigational New Drug (IND) application for ulcerative colitis in the first half of 2026, with plans to initiate Phase I and then Phase II trials.
• The leadership team comprises experienced industry professionals with expertise in drug discovery, development, commercialization, botanical medicine, and regulatory strategy.
• The company plans to adopt an equity compensation plan, setting aside 15% of outstanding share capital for key management and staff after the IPO, which can help attract and retain talent.

Negatives

• The company is a developmental stage pharmaceutical company with a limited operating history and has not generated any revenue since discontinuing health and dietary supplement sales in 2023.
• Curanex has incurred recurring net losses, reporting $(137,583) for Q1 2025 and $(361,506) for FY 2024, and anticipates continued operating losses in the foreseeable future.
• The company requires significant additional funding, estimating over $150 million to execute its full business plan through FDA approval and product launch, with no assurance of obtaining such capital.
• New investors in the IPO will experience immediate and substantial dilution of $3.5503 per share, based on an assumed IPO price of $4.00 per share.
• The development and approval process for botanical drugs involves unique challenges, including complex composition, standardization, quality control, and limited regulatory precedent (only two FDA-approved botanical drugs to date), which may lead to additional costs, delays, or failure to obtain approval.
• The company does not own any patents for Phyto-N; its provisional patent applications expired, and there is no assurance that the filed international PCT application will result in successful utility patent registration.
• The company is heavily dependent on the success of its single lead product candidate, Phyto-N, and any failure in its clinical trials or inability to obtain regulatory approval would substantially harm the business.

Risks

• Limited operating history in an evolving industry makes future prospects difficult to evaluate and increases the risk of failure.
• Failure to raise additional capital when needed will have a material adverse effect on business, financial condition, and results of operations.
• The company is a developmental stage pharmaceutical company with no commercial products and expects to incur further losses and negative cash flows.
• Inability to obtain patent protection for Phyto-N or successfully develop and commercialize it will significantly diminish future operations.
• Clinical trials have a high risk of failure, and results of earlier studies may not be predictive of future study results, potentially impairing commercial prospects.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, with no assurance of approval.
• Success is largely dependent on the ability to obtain and maintain patent protection and preserve trade secrets, which cannot be guaranteed.
• Claims by other companies for intellectual property infringement may result in liability for damages or stop development and commercialization efforts.
• Reliance on third parties for manufacturing clinical drug supplies exposes the company to various risks and uncertainties.
• There is no assurance the company will be profitable, and insufficient capital may require reduction or discontinuation of drug research and development efforts.
• Inability to manage growth effectively could cause misallocation of resources and impair or eliminate the ability to achieve and sustain profitability.
• Acquisition activity could have adverse effects, including dilutive issuances of equity, incurrence of debt, and integration difficulties.
• Reliance on highly skilled personnel, and inability to attract, retain, and motivate them, could harm the business.
• Potential legal proceedings could have a material adverse effect on business, financial condition, or results of operations.
• Risks related to compliance with corporate governance laws and financial reporting standards, including cybersecurity and data leakage risks.
• Geopolitical conditions, including trade disputes and acts of war or terrorism, could adversely affect operations and financial results.
• Inflation may adversely affect operations and financial results by increasing costs.
• No active public trading market for common stock prior to the offering, and no assurance an active market will develop or be sustained.
• The price of common stock may rapidly fluctuate or decline regardless of operating performance, resulting in substantial losses for investors.
• A possible short squeeze due to sudden increase in demand largely exceeding supply may lead to price volatility.
• Future sales of common stock or the perception of such sales may depress share price, and additional capital raises may dilute ownership.
• Founders will continue to own a significant percentage of common stock and Series A Preferred Stock, exerting significant control over shareholder matters.
• Requirements of being a public company will increase legal and financial compliance costs and divert management attention.
• Inability to satisfy Nasdaq listing requirements may result in delisting, impairing stockholders' ability to trade and raising capital.
• Failure to maintain effective internal controls over financial reporting could adversely impact public disclosures and stock price.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• As a controlled company, the company may choose to exempt itself from certain corporate governance requirements, which could adversely affect public shareholders.
• No dividends are expected to be paid in the future, limiting return on investment to stock value appreciation.
• Officers and directors will be indemnified to the maximum extent permitted by Nevada law, potentially reducing assets available for business.
• Management will have broad discretion over the use of net proceeds from the offering, and proceeds may not be invested successfully.

Future Outlook

Curanex Pharmaceuticals plans to submit an Investigational New Drug (IND) application for Phyto-N for the treatment of ulcerative colitis in the first half of 2026. If allowed by the FDA, a Phase I trial will commence 30 days post-IND submission, followed by a Phase II trial for ulcerative colitis as the lead indication. Contingent on the success of these trials and available funding, the company intends to initiate additional Phase II trials for other high-value indications such as atopic dermatitis, COVID-19, gout, diabetes, and NAFLD. The long-term vision is to explore and maximize the value of Phyto-N and build a robust pipeline of botanical drug candidates targeting inflammatory diseases, with an estimated total funding requirement of over $150 million through FDA approval and product launch.

Management Comments

• Our mission is to address significant unmet medical needs and improve patients' lives by harnessing the power of natural substances.
• We believe that our proprietary platform will allow us to create a pipeline of botanical drug candidates with potentially unique mechanisms of action to address unmet medical needs.
• Our objective is to prioritize the development of Phyto-N and its active compounds, to conduct further preclinical and clinical studies to evaluate its therapeutic potential and safety profile, and if warranted, to seek the necessary regulatory approval in order to commercialize Phyto-N.
• We aim to establish proof-of-concept for our botanical drug development platform to bring therapies that will improve life of patients who currently have limited or no effective treatment options and to generate value for our stockholders.
• We are committed to bringing hope and healing through the wisdom of plants.
• We believe that Phyto-N's key competitive advantages include its history of use in Chinese Traditional Medicine, potential multi-target mechanism of action, broad therapeutic potential, and potential for tolerability.
• We believe that our distinctive approach, combining the power of nature with scientific research and development, will set us apart in the pharmaceutical industry and positions us for long-term success.

Industry Context

The global market for inflammatory disease treatments is rapidly growing, driven by increasing prevalence and unmet medical needs. Traditional anti-inflammatory drugs often have limited efficacy and severe side effects, creating demand for innovative solutions. The botanical and plant-derived drugs market is expanding rapidly, reaching approximately $34 billion USD, as consumer preferences shift towards natural and holistic health solutions. Curanex aims to capitalize on this trend by developing botanical drugs with multi-target mechanisms, which may offer a promising new frontier in treating inflammatory diseases. However, the botanical drug development and approval process is uniquely challenging, with only two such drugs having received FDA approval to date, highlighting the innovative yet difficult nature of this niche.

Comparison to Industry Standards

• The document highlights that only two botanical drugs, Veregen (green tea extract for genital warts) and Fulyzaq/Mytesi (Croton lechleri tree derivative for HIV/AIDS diarrhea), have received FDA approval. This limited precedent underscores the unique and challenging regulatory pathway for botanical drugs compared to conventional pharmaceuticals.
• For ulcerative colitis, Phyto-N is being developed as an orally administered alternative to standard care, which includes corticosteroids, immunomodulators, and biologics like Remicade and Humira. The company suggests Phyto-N's multi-target approach may offer a wider therapeutic window compared to single-target biologics.
• In atopic dermatitis, Phyto-N is positioned as a potential oral alternative to topical steroids, calcineurin inhibitors, systemic immunosuppressants, and targeted biologics like Dupilumab (Dupixent), which has known side effects such as ocular diseases and erythema.
• For COVID-19, Phyto-N is being investigated as a potential adjunctive therapy, contrasting with current treatments like remdesivir and monoclonal antibodies, and aiming to offer the convenience of oral administration.
• In diabetes, Phyto-N offers an alternative approach to existing treatments such as metformin, insulin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, with preclinical data suggesting potential benefits in glycemic control and organ protection.
• For Nonalcoholic Fatty Liver Disease (NAFLD)/NASH, Phyto-N is being developed as a potential treatment, noting the recent FDA approval of Rezdiffra (resmetirom) as the first drug for NASH, which has associated side effects and drug interaction warnings. Phyto-N's multi-pathway approach is presented as a potential alternative.
• In gout, Phyto-N is explored as an alternative or adjunct to current treatments like Febuxostat, which carries an FDA black box warning for cardiovascular risk. Phyto-N's potential to reduce inflammatory mediators and uric acid levels is highlighted as a differentiated approach.

Management Changes

Corporate Governance

Related Party Transactions

• On June 17, 2024, Curanex entered into an Asset Purchase Agreement with Duraviva Pharma Inc., a related entity where Curanex's CEO, President, and their immediate family members are also majority shareholders, officers, and directors. Curanex acquired four provisional patent applications and eight R&D animal study reports (IP Assets) from Duraviva for $730,000 cash and 23,400,000 shares of Common Stock.
• On February 4, 2025, and May 21, 2025, Dian Ying Jing, a founder, Secretary, and wife of the CEO, provided two loans to the company, each for $200,000, totaling $400,000. These loans bear an annual interest rate of 4.34% and have maturity dates extended to February 4, 2027, and May 23, 2027, respectively.
• On January 1, 2025, the company assumed an office lease from Duraviva Pharma Inc., a related party under common control, through a lease assignment agreement. The lease extends through August 31, 2026.

Stakeholder Impact

• **Shareholders:** Existing shareholders, particularly the founding family, will retain significant control (approx. 69.3% voting power post-IPO). New investors will experience immediate and substantial dilution of $3.5503 per share. Future equity offerings could lead to further dilution. The stock price may be volatile due to limited trading volume and potential short squeezes.
• **Employees:** The company plans to adopt an equity compensation plan, setting aside 15% of outstanding share capital for key management and staff, which could incentivize and retain talent.
• **Patients:** The company's mission is to develop innovative botanical drugs to address significant unmet medical needs and improve patients' lives, particularly those suffering from inflammatory diseases. Successful development and approval of Phyto-N could provide new treatment options.
• **Creditors:** The company has outstanding loans from a related party (Dian Ying Jing) and relies on external financing, including the IPO proceeds, to fund operations and development. The going concern assessment indicates reliance on future funding.
• **Suppliers/Partners:** The company relies on third-party manufacturers for clinical drug supplies and plans to collaborate with academic institutions, CROs, and CMOs, indicating potential business opportunities for these entities.

Next Steps

• Submit an Investigational New Drug (IND) application for Phyto-N for the treatment of ulcerative colitis in the first half of 2026.
• Initiate a Phase I clinical trial for ulcerative colitis 30 days post-IND submission, if allowed by the FDA.
• Proceed with a Phase II trial for ulcerative colitis as the lead indication, contingent on positive Phase I results.
• Potentially initiate additional Phase II trials in other high-value indications (atopic dermatitis, COVID-19, gout, diabetes, NAFLD), contingent on success of ulcerative colitis trials and available funding.
• Continue to invest in translational research to further elucidate mechanisms of action, biomarkers, and patient stratification strategies for Phyto-N.
• Identify and isolate active chemical compounds from Phyto-N to potentially serve as the basis for novel small molecule drugs.
• Seek strategic partnerships for co-development, co-promotion, or out-licensing of drug candidates.
• Pursue non-dilutive funding opportunities such as research grants and contracts.
• Establish manufacturing, supply chain, and distribution capabilities, potentially partnering with Contract Manufacturing Organizations (CMOs).
• Adopt an equity compensation plan immediately after the IPO, setting aside 15% of outstanding share capital for employee stock options.

Key Dates

Keywords

Pharmaceuticals, Botanical Drugs, Inflammatory Diseases, Phyto-N, Initial Public Offering, IPO, Nasdaq, Ulcerative Colitis, Atopic Dermatitis, COVID-19 Treatment, Diabetes Treatment, Nonalcoholic Fatty Liver Disease, NAFLD, Gout Treatment, Preclinical Studies, Clinical Trials, SEC Filing, Drug Development, Biotechnology, Corporate Governance, Risk Factors, Capital Raise